The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
are really in a pickle right now..
no one is selling, you dont have the oh ive been spiked brigade and want to get out, noone is sitting on losses right now..
day traders arent existent, they drop Bid to scare sellers and if that happens is they get buyers grabbing the shares.
only other avenue is hoping the hnwi selling shares but that isnt happening..
so all they can do is trade sidways. game of attrition
it could be as simple as they are biding their time.
they will get their final data for Mome early 2022. and if thats good that drug could be on the market very soon after that. that brings in their revenue and then they push on with chk1
quite simple
in the time Sierra have had chk1 they made excellent progress with it- until they stopped. they have proven how good it is..
they mess up we get it back - we licence it to someone else to finish the job...
but for whatever reason. i think they do have a plan.. what it is who knows, but Gilead will play a big part in it.
https://m.media-amazon.com/images/I/518l-qsQorL._AC_UX679_.jpg
over at advfn- theyve settled the question of the 5m for 30m of funding - it is not Agile
but this
https://www.theguardian.com/technology/2021/jul/20/government-sets-up-375m-fund-for-gamechanging-uk-tech-firms?CMP=Share_AndroidApp_Other
took me 2 seconds
https://www.cdc.gov/coronavirus/2019-ncov/lab/grows-virus-cell-culture.html
think you may have a case of overthinking it.. the wording of invention seems to be a common jargon linked with patents
as its been used previously by Sar as in a previous RNS
https://www.lse.co.uk/rns/SAR/us-patent-allowance-sdc-1802-tyk2jak1-inhibitor-d7t06xmzktdw7lc.html